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The objective of this study was to elucidate the mechanisms by which
nitric oxide (NO) inhibits rat aortic smooth muscle cell (RASMC)
proliferation. Two products of the arginine-NO pathway interfere
with cell growth by distinct mechanisms. NG-hydroxyarginine and NO
appear to interfere with cell proliferation by inhibiting arginase and
ornithine decarboxylase (ODC), respectively. S-nitroso-N-acetylpeni-
cillamine, (Z)-1-[N-(2-aminoethyl)-N-(2-aminoethyl)-amino]-diazen-1-
ium-1,2-diolate, and a nitroaspirin derivative (NCX 4016), each of
which is a NO donor agent, inhibited RASMC growth at concentra-
tions of 1–3 mM by cGMP-independent mechanisms. The cytostatic
action of the NO donor agents as well as a-difluoromethylornithine
(DFMO), a known ODC inhibitor, was prevented by addition of
putrescine but not ornithine. These observations suggested that NO,
like DFMO, may directly inhibit ODC. Experiments with purified,
recombinant mammalian ODC revealed that NO inhibits ODC possibly
by S-nitrosylation of the active site cysteine in ODC. DFMO, as well as
the NO donor agents, interfered with cellular polyamine (putrescine,
spermidine, spermine) production. Conversely, increasing the expres-
sion and catalytic activity of arginase I in RASMC either by transfec-
tion of cells with the arginase I gene or by induction of arginase I
mRNA with IL-4 resulted in increased urea and polyamine production
as well as cell proliferation. Finally, coculture of rat aortic endothelial
cells, which had been pretreated with lipopolysaccharide plus a
cytokine mixture to induce NO synthase and promote NO production,
caused NO-dependent inhibition of target RASMC proliferation. This
study confirms the inhibitory role of the arginine-NO pathway in
vascular smooth muscle proliferation and indicates that one mecha-
nism of action of NO is cGMP-independent and attributed to its
capacity to inhibit ODC.
cGMP u NG-hydroxyarginine u atherosclerosis u ornithine
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N itric oxide (NO) is a physiological mediator of numerouscellular and organ functions (1), including inhibition of cell
proliferation (2, 3). The mechanism by which NO inhibits cell
proliferation appears to be multifaceted in that both cGMP-
dependent and cGMP-independent mechanisms may be in-
volved (2–5). After critical evaluation of the literature, we
concluded that the evidence for involvement of cGMP in ex-
pression of the cytostatic effect of NO was indirect and incon-
sistent. Unpublished experiments in this laboratory consistently
revealed cGMP-independent cytostatic effects of NO in various
mammalian cell types including Caco-2 tumor cells, murine
macrophages, rat aortic endothelial cells (RAEC), and rat aortic
smooth muscle cells (RASMC). Therefore, our focus of atten-
tion has been on cGMP-independent mechanisms by which NO
and the arginine-NO pathway inhibit cell proliferation. One such
mechanism appears to be inhibition of two critical enzymes in
the arginine-polyamine pathway, resulting in decreased poly-
amine production and consequent interference with cell prolif-
eration (2, 3, 6, 7). NO is not the only product of NO synthase
(NOS) that inhibits cell proliferation. N-hydroxyarginine
(NOHA), the principal intermediate in the NOS-catalyzed
conversion of arginine to NO plus citrulline, is also a potent
competitive inhibitor of arginase (7, 8) and inhibitor of tumor
cell proliferation (2). NOHA appears to interfere with tumor cell
proliferation by cGMP-independent mechanisms involving the
inhibition of arginase (2). NO has been found to be an inhibitor
of ornithine decarboxylase (ODC) (2, 3, 6) and, like a-dif luo-
romethylornithine (DFMO), can inhibit tumor cell proliferation
by this cGMP-independent mechanism. Therefore, two products
of NOS are capable of interfering with tumor cell proliferation
by inhibiting two sequential steps in the arginine-polyamine
pathway by cGMP-independent mechanisms. Arginase, which
catalyzes the conversion or arginine to ornithine plus urea, is
important not only in the urea cycle in the liver (arginase I
isoform) but also in biochemical pathways essential to cell
growth and wound healing in all cells (arginase I and II iso-
forms). Ornithine is, in turn, converted to putrescine by ODC,
following which putrescine is converted to spermidine and
spermine. The three polyamines (putrescine, spermidine, sperm-
ine) are required for mammalian cell growth (9).
Atherosclerosis is a complex inflammatory condition involving
the arterial vascular bed, and early vascular lesions are character-
ized by increased monocyteymacrophage invasion, proliferation,
and activation as well as increased vascular smooth muscle prolif-
eration (10). Another feature of early lesions in atherogenesis is
distinct vascular endothelial cell dysfunction characterized by im-
paired endothelium-derived NO production and impaired endo-
thelium-dependent vasodilation (10–12). Considering the possibil-
ity that one function of the arginine-NO pathway may be to inhibit
or modulate cell proliferation, a deficiency in endothelial NO
production could account, at least in part, for the increased
proliferation of monocytesymacrophages and vascular smooth
muscle that occurs in atherosclerosis. NO as well as activation of
NOS have been reported to inhibit vascular smooth muscle cell
proliferation (13, 14). Therefore, the objective of the present study
was to elucidate the mechanisms by which NO and the arginine-NO
pathway bring about inhibition of vascular smooth muscle cell
proliferation in an in vitro cell culture model using RASMC.
Materials and Methods
Chemicals and Solutions. Sources of lipopolysaccharide, cytokines,
cell culture media and supplements, and reagents for urea
determination, arginase assay, ODC assay, and protein deter-
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mination have been described (2, 6, 7). NOHA was obtained
from Cayman Chemicals (Ann Arbor, MI), S-ethylisothiourea
was from TCI America (Portland, OR), and zaprinast was from
Sigma. NG-methylarginine and S-nitroso-N-acetylpenicillamine
(SNAP) were synthesized as described (15, 16). 1H-(1,2,4)ox-
adiazolo[4,3-a]quinoxalin-1-one (ODQ) was purchased from
Alexis Biochemicals (San Diego). (Z)-1-[N-(2-aminoethyl)-N-
(2-aminoethyl)-amino]-diazen-1-ium-1,2-diolate (DETA-NO)
and 1,1-diethyl-2-hydroxy-2-nitroso-hydrazine (DEA-NO) were
generously provided by David A. Wink, National Institutes of
Health, Bethesda, MD. NCX 4016 was provided by NicOx. All
other chemicals and reagents were obtained from Sigma unless
specified otherwise.
Cell Culture of RASMC and Measurement of Cell Proliferation.
RASMC were a generous gift from Steven Gross, Cornell Medical
College, New York. Cells were plated, grown, subcultured, and
cultured as described (17). Subcultured strains were used between
passages 15 and 25. Exponentially growing RASMC were
trypsinized and resuspended in fresh DMEM-Hepes medium sup-
plemented with 10% (volyvol) FBS, 2 mM glutamine, 100 unitsyml
penicillin, and 100 mgyml streptomycin. The cells were seeded in
12-ml plates at a density of 3 3 103 cellsycm2 and incubated at 37°C
in a humidified atmosphere of 5% CO2-95% air. After 24 h the cells
were washed twice with PBS. The growth medium was replaced
with 1 ml of arginine-free DMEM-Hepes supplemented with 5%
FBS and 50 mM L-arginine, and any test agents and 0.5 mCi
[3H]thymidine (6.7 Ciymmol; NEN) were added. In determining
the rates of DNA synthesis, a modification of the [methyl-
3H]thymidine incorporation procedure described previously (2)
was used. Cell proliferation data are expressed as percent of
control, as described (2).
Coculture Procedures. RAEC were plated on Falcon cell culture
inserts on polyethylene terephthalate track-etched membranes with
3-mm pore size (Becton Dickinson). Cells were seeded at a density
of 4.5 3 104 cellsycm2 in DMEM-Hepes containing 20% FBS, 1%
endothelial growth supplement, 2 mM L-glutamine, 100 unitsyml
penicillin, 100 mgyml streptomycin, 1 mM sodium pyruvate, and 10
unitsyml heparin, and incubated at 37°C in a humidified atmo-
sphere of 5% CO2-95% air. Cells were allowed to attach and the
medium was changed the next day and then every other day. At
confluence (3–4 days), some of the cells were activated by addition
of lipopolysaccharide (100 mgyml), IFN-g (100 unitsyml), IL-1b
(400 unitsyml), and tumor necrosis factor a (1,000 unitsyml) and
subsequently incubated for 6 h, followed by removal of lipopoly-
saccharide and cytokines by extensive washing before coculture
with RASMC as follows. The medium was replaced after washing
RAEC twice with arginine-free and serum-free medium (Specialty
Media, Lavellette, NJ), containing 2 mM L-glutamine, 100
unitsyml penicillin, 100 mgyml streptomycin, 1 mM sodium pyru-
vate, and SITE13 serum supplement. The nonactivated RAEC
cultured on inserts also were washed. RASMC were seeded at a
density of 104 cellsycm2 in 6-well companion plates for the inserts
in DMEM-Hepes containing 10% FBS, 2 mM L-glutamine, 100
unitsyml penicillin, 100 mgyml streptomycin, and 1 mM sodium
pyruvate. The cells were synchronized for 48 h by washing twice
with PBS and replacing the medium with arginine-free and serum-
free supplemented medium as described above. The activated and
nonactivated RAEC that had been plated on the inserts were added
to the wells containing the synchronized RASMC. An equal
number of wells contained only RASMC. To each well and each
insert, 1 ml of serum-free supplemented medium containing 100
mM L-arginine was added. After 24 h of coculture, 0.5 mCi of
[methyl-3H]thymidine was added to each well, inserted, and incu-
bated for another 24 h, after which time DNA synthesis in RASMC
was assessed.
Determination of Polyamine Concentrations in Cells. The concentra-
tions of putrescine, spermidine, and spermine in RASMC were
determined by a sensitive HPLC procedure (18). RASMC were
plated at a density of 106 cells per 100-mm dish and grown to 80%
confluence before the start of experiments. After 24-h incuba-
tion of RASMC with the indicated test agents, the cells (’5 3
106) in each dish were rapidly washed twice with ice-cold PBS
and then lysed in 0.5 ml of 1.5 M HClO4, and the solution was
neutralized by the addition of 0.25 ml K2CO3. The neutralized
extracts were used for determination of polyamines.
ODC Assay. ODC activity was determined by monitoring the
formation of [14C]CO2 from L-[1-14C]ornithine exactly as de-
scribed (6).
Arginase Assay. Arginase activity was determined by methods that
we have described (7). Briefly, RASMC (5 3 106 cellsysample)
were washed twice with ice-cold PBS, harvested, pelleted by
centrifugation, and then lysed. Supernatant fractions were assayed
for arginase activity under optimal conditions of pH (9.6) and
arginine concentration (20 mM) by monitoring the conversion of
L-[guanido-14C]arginine to [14C]urea during 10-min incubation.
Determination of Urea Concentrations in Cell Culture Medium. Nor-
mal RASMC, IL-4-treated RASMC, control-transfected
RASMC, and arginase I-transfected RASMC were analyzed for
urea production by determination of urea released into the cell
culture medium. Cell culture media were collected and analyzed
spectrophotometrically for urea exactly as described (7).
Determination of cGMP Levels in Cells. At 24 h before initiation of
experiments, 106 RASMC were plated in 60-mm dishes. At the
start of experiments, zaprinast or ODQ was added 30 min before
addition of SNAP. Incubations were continued for exactly 30 sec,
after which time cGMP was extracted from cells by using ice-cold
65% ethanol as follows. The cell culture medium was aspirated
and discarded, and the cells were washed twice with 4 ml of
ice-cold PBS. The ethanol was added to the cells in each dish and
the cells were scraped and transferred into a microcentrifuge
tube. The dish was washed with 0.5 ml of 65% ethanol and added
to the ethanol cell extract in the corresponding tube. Samples
were sonicated briefly and centrifuged at 5,000 g for 15 min at
4OC. The clear supernatants were transferred to fresh tubes, and
the ethanol was evaporated under a stream of nitrogen at 60°C.
The samples were then redissolved in 1.1 ml of sample buffer
(0.05 M sodium acetate, pH 5.8). cGMP was assayed by RIA
following the acetylation assay protocol as described by the
manufacturer (Amersham Pharmacia, catalog no. RPA 525).
Vector Construction and Transfection of RASMC. pEF1-rARGI, a
mammalian expression plasmid for rat arginase I, was con-
structed by inserting the EcoRI–BsaAI 1,194-bp coding region
fragment of pARGr-2 (19) into the EcoRIyPmel sites of the
plasmid pEF1yMyc-His C. No additional epitope sequences
were fused to the arginase I coding sequence in this construct.
For control transfection, the b-galactosidase expression plasmid
(pEF1yMyc-HisylacZ) alone, which contains the Escherichia
coli lacZ gene under control of the human EF-1a promoter
(Invitrogen), was used to represent the expression of an unre-
lated exogenous protein. RASMC were transfected with
pEF1yrARGI or pEF1yMyc-HisylacZ by using Lipofectamine
(Life Technologies, Grand Island, NY) according to the manu-
facturer’s instructions. Stably transfected cells were selected with
the antibiotic G418 (500 mgyml) in complete DMEM. Cells were
maintained at 37°C in complete DMEM containing 10% FBS
and 500 mgyml G418. After approximately 3 weeks, G418-
resistant clones were isolated and analyzed individually for
expression of arginase I. The individual clones were grown in









DMEM containing 10% FBS and 250 mgyml G418. The G418
was omitted from the cell culture medium beginning 2 days
before initiating any experiments. Stably transfected RASMC
were examined for expression of arginase I by Western blot
analysis as described (17).
Statistical Analyses. Where indicated, data were analyzed statisti-
cally by using the Bonferroni t test for unpaired values. Probability
values of ,0.05 were taken to indicate statistical significance.
Results
We have reported previously that NOHA and NO, products of the
arginine-NO pathway, inhibit tumor cell proliferation (2). Fig. 1
illustrates that NO interferes also with the proliferation of vascular
smooth muscle cells from rat aorta. SNAP, an S-nitrosothiol NO
donor agent, and DETA-NO, a NONOate NO donor agent, each
inhibited RASMC proliferation in a concentration-dependent
manner. SNAP was slightly more potent than DETA-NO, eliciting
significant effects at a concentration of 1 mM. NCX 4016, a nitro
analog of aspirin that can serve as a NO donor agent in vivo or in
vitro in the presence of cells or tissues (20–22), inhibited RASMC
proliferation with a potency equivalent to that of SNAP. Aspirin
(acetylsalicylic acid) tested at 1 mM to 1 mM was completely
inactive (data not shown). DFMO, a well established ODC inhibitor
and cytostatic agent, was used as a positive control test agent, and
it inhibited RASMC proliferation at relatively high concentrations
ranging from 0.1 to 1 mM.
DFMO inhibits cell growth by inhibiting the ODC-catalyzed
conversion of ornithine to putrescine and thereby interfering with
polyamine synthesis (23). In cell culture, the cytostatic action of
DFMO can be prevented or overcome by the addition of excess
putrescine (product of ODC) but not excess ornithine (substrate for
ODC and product of arginase) (2), as illustrated in Fig. 2. On the
other hand, the cytostatic action of NOHA, a potent inhibitor of
arginase (8), can be prevented by addition of either excess pu-
trescine or excess ornithine (2), as illustrated in Fig. 2. The cytostatic
actions of SNAP and NCX 4016 were prevented by addition of
excess putrescine but not ornithine, thereby resembling the effects
of DFMO rather than NOHA (Fig. 2). These observations support
the view that NO interferes with cell proliferation by inhibiting
ODC, whereas NOHA may interfere with cell proliferation by
inhibiting arginase, as was found in tumor cells (2).
The next step was to verify that NO, like DFMO, interferes with
polyamine production, as might be expected for chemical agents
that inhibit ODC. DFMO was tested as a positive control and
inhibited the formation and accumulation of putrescine, spermi-
dine, and spermine (Fig. 3). Polyamine production was inhibited
also by SNAP, DETA-NO, and NCX 4016 at concentrations that
interfered with RASMC proliferation. These observations are
consistent with the finding that NO directly inhibits ODC (2, 3, 6).
Indeed, SNAP and DEA-NO inhibited mammalian recombinant
ODC in a concentration-dependent manner (Fig. 4). DFMO was
tested as a positive control. NCX 4016 was not active, presumably
because this nitro derivative of aspirin must first be metabolized to
aspirin and NO before the effects of NO can be observed (20).
Metabolic conversion of NCX 4016 would be expected to occur in
vivo and in vitro in the presence of cells or tissues but not in an
isolated, purified ODC reaction mixture.
Some of the biological actions of NO are known to be
mediated by the second messenger actions of cGMP (24). These
actions include vascular smooth muscle relaxation and inhibition
of platelet aggregation. The evidence that cGMP is involved in
the cytostatic action of NO is inconsistent and controversial
(2–5). Experiments were conducted here to ascertain whether or
not cGMP can account for the inhibitory action of NO on
Fig. 1. Inhibition of RASMC proliferation by SNAP, DETA-NO, NCX 4016
(NCX), and DFMO. Cell proliferation was assessed by thymidine incorporation
into DNA during the final 24 h of RASMC incubation, as described in the text.
Test agents were added to cells at the time of thymidine addition. The
concentrations of test agents were (from left to right for each test agent):
SNAP, 1, 3, 10, and 30 mM; DETA-NO, 3, 10, 30, and 100 mM; NCX, 1, 3, 10, and
30 mM; DFMO, 100 mM, 300 mM, and 1 mM. Data were calculated as dpm per
105 cells per well and expressed as percentage of control (assigned 100%),
where control represents cells grown in the absence of added test agents. Each
of the points was significantly different (P , 0.05) from control (100%) except
the value for 3 mM DETA-NO (P . 0.05). Data represent means 6 SE of
duplicate determinations from 3–4 separate experiments.
Fig. 2. Influence of added putrescine or ornithine on the cytostatic actions
of DFMO, SNAP, NCX 4016 (NCX), and NOHA in RASMC. Cell proliferation was
assessed by thymidine incorporation into DNA during the final 24 h of RASMC
incubation, as described in the text. Test agents were added to cells at the time
of thymidine addition. Putrescine (100 mM) or ornithine (100 mM) was added
to cells at the same time as the test agents. Data were calculated as dpm per
105 cells per well and expressed as percentage of control (assigned 100%),
where control represents cells grown in the absence of added test agents. *
signifies statistically significant difference (P , 0.05) from corresponding
control (no additions). Data represent means 6 SE of duplicate determinations
from four separate experiments.
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RASMC proliferation. First, it was necessary to conduct exper-
iments to determine whether NO can stimulate cGMP produc-
tion in RASMC under the defined experimental conditions.
SNAP was used as the NO donor agent and concentrations
ranging from 1 mM to 1 mM were added to cells for various time
intervals ranging from 0 to 5 min before ice-cold 65% ethanol
was added to cells and assayed for cGMP. A 30-sec time interval
was found to be the most consistent time interval for peak cGMP
accumulation in response to added SNAP (data not shown) and
was used in the experiments. Fig. 5 illustrates that 30 mM SNAP
caused a greater than 2-fold accumulation of cGMP in RASMC
and this effect was abolished by addition of 10 mM ODQ
(guanylyl cyclase inhibitor) (25) and enhanced by addition of 30
mM zaprinast (cGMP phosphodiesterase inhibitor) (26). Thus,
the NO-cGMP signal transduction pathway is present and func-
tional in RASMC under the present assay conditions. However,
the NO-cGMP signal transduction system does not appear to be
involved in the cytostatic action of NO in RASMC. For example,
neither ODQ nor zaprinast, at concentrations that influenced
cellular cGMP levels (Fig. 5), affected the cytostatic action of
SNAP, DETA-NO, and NCX 4016 in RASMC (Fig. 6). More-
over, neither ODQ nor zaprinast influenced control cell prolif-
eration. These observations indicate that NO inhibits RASMC
growth largely by cGMP-independent mechanisms.
The present study and a previous study from this laboratory
(2) indicate that NO and NOHA interfere with cell proliferation
by mechanisms associated with the inhibition of ODC and
arginase, respectively. One likely mechanism that may account
for inhibition of RASMC proliferation is decreased polyamine
production, as shown for NO and NCX 4016 above. The next
experiment was designed to determine whether the opposite is
true, that is, if an increase in arginase activity in RASMC results
in an increase in cell proliferation. To obtain RASMC with
elevated expression of arginase, cells were either treated with
IL-4, which causes induction of arginase I (17), or stably trans-
fected with an expression plasmid containing rat arginase I
cDNA. RASMC stably transfected with the expression plasmid
vector alone represented control transfected cells. Fig. 7 illus-
trates that the induction of arginase I in RASMC by IL-4 (10
Fig. 3. Inhibition of polyamine production in RASMC by DFMO, SNAP,
DETA-NO, and NCX 4016 (NCX). Test agents were added to RASMC 24 h before
determination of polyamine concentrations. Cells were washed, lysed, and
extracted as described in the text. Concentrations of spermidine and spermine
are expressed as nmol per 107 cells. Putrescine concentrations are actually
100-fold lower than indicated and, therefore, should be multiplied by 1022 to
obtain the true values. All values for polyamine concentrations in the presence
of added test agents were significantly different (P , 0.05) from values for
control (CTL). Data represent means 6 SE of duplicate determinations from
4–5 separate experiments.
Fig. 4. Inhibition of purified ODC by SNAP, DEA-NO, NCX 4016 (NCX) and
DFMO. DTT was separated from the enzyme by gel filtration through a
Sephadex G-25 column. ODC was preincubated with the test agents, as
indicated, at 37°C for 15 min. Enzyme mixture was then added to assay buffer
containing 0.4 mM ornithine (labeled with 0.1 mCi L-[1-14C]ornithine; 55
Ciymmol) and 40 mM pyridoxal 59-phosphate. ODC activity was measured
after 30-min incubation at 37°C as described (6). All concentrations of SNAP,
DEA-NO, and DFMO tested inhibited ODC significantly (P , 0.05). NCX was not
active (P . 0.05). CTL, control. Data represent means 6 SE of duplicate
determinations from four separate experiments.
Fig. 5. StimulationofcGMPproduction inRASMCbySNAP.RASMCweregrown
to 80% confluence and used in experiments. Cells were pretreated with ODQ or
zaprinast as indicated for 15 min. SNAP was added for 30 sec, after which time cell
incubations were terminated by addition of 4 ml of ice-cold 65% ethanol. Cells
were extracted with ethanol, and extracts then were assayed for cGMP as de-
scribed in the text. * signifies that values were significantly different (P , 0.05)
from control (no additions). ** signifies that values were significantly different
(P , 0.05) from corresponding control values (absence of SNAP). Data represent
means 6 SE of triplicate determinations from three separate experiments.









ngyml) was associated with a 50% increase in urea production
and cell proliferation. IL-4 also caused a 50% increase in
polyamine (spermidine and spermine) production after 24 h
incubation with RASMC (data not shown). Similarly, increased
arginase I expression in RASMC afforded by transfection of cells
with arginase I cDNA was associated with comparable increases
in urea production and cell proliferation (Fig. 8) and polyamine
(spermidine and spermine) production (data not shown).
The final experiment in this study was designed to determine
whether coculture of RAEC, after induction of inducible NOS
to promote NO production, with RASMC could influence
RASMC proliferation. Untreated RAEC caused a slight inhi-
bition of RASMC proliferation but this cytostatic effect was
markedly increased when RASMC were cocultured with RAEC
that had been activated (pretreated) with lipopolysaccharide
plus a cytokine mixture as described in Materials and Methods
(Fig. 9). This enhanced cytostatic effect appears to be attributed
to increased production of NO, and perhaps NOHA, because
addition of either NG-methylarginine or S-ethylisothiourea (in-
hibitors of inducible NOS) to cell cocultures essentially abolished
the cytostatic action of activated RAEC. These observations
reveal that NO andyor NOHA generated by RAEC can diffuse
into nearby RASMC and inhibit RASMC proliferation.
Discussion
The principal objective of the present study was to develop a
better understanding of the mechanisms by which NO and the
arginine-NO pathway interfere with the proliferation of vascular
smooth muscle. An in vitro cell culture model was used in which
the proliferation of RASMC was monitored by [3H]thymidine
incorporation into cellular DNA. NO, in the form of three
chemically distinct NO donor agents, inhibited RASMC prolif-
eration at concentrations down to 1 to 3 mM. The potency of NO
in inhibiting RASMC proliferation may have been much greater
than was apparent in this study. The actual concentrations of NO
generated from the NO donor agents used were probably much
lower than the concentrations of the NO donor agents them-
selves. For example, 1 mM DETA-NO in aqueous solution
liberates ’3 mM NO under steady-state conditions (27). This
means that NO was an effective cytostatic agent at low nano-
molar concentrations in the present study. We reported previ-
ously that NOHA and NO interfere with human Caco-2 tumor
cell growth by inhibiting arginase and ODC, respectively (2). The
same mechanisms appear to be operational in RASMC, as
shown in the present study. For example, the cytostatic effect of
NOHA was prevented by addition of excess ornithine or pu-
trescine to cell cultures, whereas the cytostatic effect of NO was
prevented by addition of excess putrescine but not ornithine.
These observations support the views not only that NOHA and
NO interfere with two distinct enzymatic steps in the arginine-
polyamine pathway (2), but also that interruption of polyamine
production can cause inhibition of cell proliferation (19). Indeed,
the present study reveals that NO inhibits polyamine production
in RASMC.
We believe that one important mechanism by which NO
interferes with cell proliferation in general is by direct inhibition
of ODC (2, 3, 6) and consequent inhibition of polyamine
production. This mechanism applies also to RASMC, as dem-
onstrated in this report. Preliminary experiments revealed that
NO (SNAP) inhibited crude ODC extracted from RASMC, and
more extensive experiments showed the inhibitory effects of
NO-donor agents on purified, mammalian, recombinant ODC.
The mechanism of inhibition of ODC by NO appears to be
S-nitrosylation of the active site cysteine 360 residue, thereby
inactivating the enzyme because the cysteine 360 sulfhydryl is
essential for the expression of catalytic activity (28, 29). As we
Fig. 6. Influence of added ODQ or zaprinast on the cytostatic actions of
SNAP, DETA-NO, and NCX 4016 (NCX). Cell proliferation was assessed by
thymidine incorporation into DNA during the final 24 h of RASMC incubation,
as described in the text. Test agents were added to cells at the time of
thymidine addition. ODQ (10 mM) or zaprinast (30 mM) was added to cells at
the same time as the test agents. Data were calculated as dpm per 105 cells per
well and expressed as such. Values for SNAP, DETA-NO, and NCX were not
significantly different (P . 0.05) from corresponding values in the presence of
either ODQ or zaprinast, but were significantly different (P , 0.05) from
control (CTL) values. Values for ODQ or zaprinast alone were not significantly
different (P . 0.05) from control values. Data represent means 6 SE of
duplicate determinations from four separate experiments.
Fig. 7. Influence of IL-4 on arginase activity, urea production, and cell
proliferation in RASMC. RASMC were plated at a density of 106 cells per
100-mm dish and grown to 80% confluence before the start of experiments.
After 24-h incubation of RASMC with 10 ngyml IL-4, the cells (’5 3 106) in each
dish were ready for analysis. Some dishes were used for assessment of cell
proliferation, whereas other dishes were used for determination of both urea
and arginase activity. Cell proliferation was assessed by thymidine incorpora-
tion into DNA during the final 24 h of RASMC incubation, as described in the
text. In separate dishes, cells were harvested and washed with ice-cold PBS,
and the suspensions were centrifuged to sediment the cells. Sediments were
lysed, and supernatants were assayed for arginase activity as described in the
text. Cell culture media from the cells used for determination of arginase
activity were collected for determination of urea levels, as described in the
text. * signifies that values were significantly different (P , 0.05) from corre-
sponding control values. Data represent means 6 SE of duplicate determina-
tions from 4–5 separate experiments.
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have noted previously, S-nitrosylation of ODC by various chem-
ical classes of NO donor agents may occur by slightly different
chemical mechanisms (6). For example, S-nitrosothiols may
covalently modify the cysteine 360 sulfhydryl by S-transnitrosa-
tion reactions, where the NO is readily transferred from the
sulfur atom of the S-nitrosothiol to the sulfur atom of the
cysteine 360 sulfhydryl. On the other hand, the NONOates
generate pure NO, which then likely reacts with O2 to form
N2O3, which in turn is a potent nitrating agent. We have
suggested that one physiological function of endogenous S-
nitrosothiols might be to modulate cell proliferation by slowing
it down (6).
Clearly, NO inhibits ODC by cGMP-independent mecha-
nisms, and this mechanism is likely to represent at least one of
the cGMP-independent components of the overall physiological
process by which endogenous NO modulates cell proliferation.
NO itself, NO donor agents, and NOS activation have been
reported to inhibit the proliferation of various cell types from
diverse species by either or both cGMP-dependent and inde-
pendent mechanisms (2–5). Whether or not cGMP represents a
signal transduction mechanism in the expression of the antipro-
liferative action of NO has been a point of controversy. In the
present study, cGMP was found not to be involved in the
antiproliferative action of NO in RASMC. Likewise, in a pre-
vious study, NO and NOHA inhibited human Caco-2 tumor cell
proliferation by cGMP-independent mechanisms (2). Therefore,
NO and the arginine-NO pathway can cause inhibition of cell
proliferation largely by cGMP-independent mechanisms. It
seems reasonable to consider, however, that the arginine-NO
pathway functions to inhibit cell proliferation by more than one
mechanism, and one mechanism might be cGMP-dependent.
Two or more mechanisms might serve as back up, alternate, or
complementary mechanisms.
One important physiological role of the arginine-NO pathway
is to protect the cardiovascular system against pathophysiological
insults that can lead to chronic disease such as hypertension,
stroke injury, and atherosclerosis (30). A deficiency in the
production of NO by altered vascular endothelial cells is likely
to be involved in the development or progression of atheroscle-
rosis (10, 11, 30). Coronary artery disease and atherosclerosis in
general are considered to be chronic inflammatory processes
characterized by invasion of vascular tissue by certain circulating
blood cells, which then proliferate and elaborate factors that
cause the underlying vascular smooth muscle to proliferate,
eventually resulting in plaque formation, lumen occlusion, and
plaque rupture. In view of the known chemical and biological
properties of NO and the arginine-NO pathway, it is not
unreasonable to speculate that this pathway functions in normal
healthy vascular endothelial cells in multiple ways to prevent
adhesion and migration of monocytes and leukocytes at the
intimal surface, to act as an antioxidant to prevent oxidative
stress-related oxidation of lipoproteins, and to prevent prolifer-
ation of white blood cells and vascular smooth muscle cells. The
findings in the present report that the arginine-NO pathway is
capable of interfering with vascular smooth muscle proliferation
support this view.
A new class of NO donor agent has emerged in which the class
members are clinically used nonsteroidal antiinf lammatory
drugs that are chemically linked to a readily hydrolyzable nitrate
ester moiety (20). These nitrated drugs are hydrolyzed in vivo
with the liberation of both NO and the nonsteroidal antiinflam-
matory drug itself. The representative compound used in the
present study is nitroaspirin (NCX 4016). Nitroaspirin inhibited
RASMC proliferation with a potency equivalent to that of NO
and by mechanisms that appear to involve NO. Aspirin alone did
not affect cell proliferation. The cytostatic effect of nitroaspirin,
like that of NO, was prevented by added putrescine but not
ornithine, was cGMP-independent, and was associated with
concomitant inhibition of polyamine production. Nitroaspirin
Fig. 8. Influence of arginase I transfection on arginase activity, urea pro-
duction, and cell proliferation in RASMC. Transfection procedures are de-
scribed in the text. RASMC were grown in 100-mm dishes and reached ’5 3
106 cells per dish just before analysis. Some dishes were used for assessment of
cell proliferation, whereas other dishes were used for determination of both
urea and arginase activity. Cell proliferation was assessed by thymidine incor-
poration into DNA during the final 24 h of RASMC incubation, as described in
the text. In separate dishes, cells were harvested and washed with ice-cold PBS,
and the suspensions were centrifuged to sediment the cells. Sediments were
lysed and supernatants were assayed for arginase activity as described in the
text. Cell culture media from the cells used for determination of arginase
activity were collected for determination of urea levels, as described in the
text. * signifies that values were significantly different (P , 0.05) from corre-
sponding control values. Data represent means 6 SE of duplicate determina-
tions from 3–5 separate experiments.
Fig. 9. Influence of NO-producing, activated RAEC on RASMC proliferation.
Coculture, RAEC activation, and cell proliferation procedures are described in
the text. As indicated, either 1 mM NG-methylarginine (NMA) or 0.1 mM
S-ethylisothiourea (EITU) was added to cocultures at the start of coculture.
After 24 h of coculture, 0.1 mCi of [methyl-3H]thymidine was added to each
well and to each insert and incubated for another 24 h, after which time DNA
synthesis in RASMC was assessed. * signifies that values were significantly
different (P , 0.05) from values for RASMC alone. Data represent means 6 SE
of duplicate determinations from 3–4 separate experiments.









differed from the other NO donor agents, however, in that
nitroaspirin failed to cause direct inhibition of ODC. A likely
explanation for this lack of effect is that nitroaspirin is a stable
compound that requires enzymatic hydrolysis to liberate NO
(20) and this does not appear to occur in buffer containing
purified ODC in the absence of added esterases or other factors.
Interestingly, nitroaspirin was reported to reduce infarct size in
a rat model of myocardial infarction without causing hypoten-
sion or a negative inotropic effect, as was the case with NO donor
agents such as DETA-NO (31). Nitroaspirin releases NO in vivo
without causing any apparent changes in systemic blood pressure
(32). Whether this is attributed to the slow enzymatic release of
NO from nitroaspirin (33) remains to be determined. Clinical
trials of nitroaspirin and other NO-releasing analogs of nonste-
roidal antiinflammatory drugs in cardiovascular disease such as
atherosclerosis will be of interest. The combined antiinflamma-
tory actions and other actions of aspirin and NO along with the
antiproliferative action of NO might result in a clinically effective
drug for the early treatment of atherosclerosis.
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